EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Ojemda (tovorafenib) to treat patients aged 6 months and older with paediatric low-grade glioma (a type of brain tumour).
Ojemda can be used when the tumour has certain changes in the BRAF gene (such as a BRAF fusion, rearrangement or V600 mutation) in patients whose disease has worsened despite previous treatment with one or more systemic medicines.